WO1993014070A3 - Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques - Google Patents

Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques Download PDF

Info

Publication number
WO1993014070A3
WO1993014070A3 PCT/FR1993/000015 FR9300015W WO9314070A3 WO 1993014070 A3 WO1993014070 A3 WO 1993014070A3 FR 9300015 W FR9300015 W FR 9300015W WO 9314070 A3 WO9314070 A3 WO 9314070A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
imidazole derivatives
therapeutic applications
novel imidazole
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1993/000015
Other languages
English (en)
Other versions
WO1993014070A2 (fr
Inventor
Jean-Charles Schwartz
Jean-Michel Arrang
Monique Garbarg
Jeanne-Marie Lecomte
Charon Robin Ganellin
Abdellatif Fkyerat
Wasyl Tertiuk
Walter Schunack
Ralph Lipp
Holger Stark
Katja Purand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Bioprojet SC
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/117,161 priority Critical patent/US5559113A/en
Priority to JP51219193A priority patent/JP3829259B2/ja
Priority to US09/544,755 priority patent/USRE37303E1/en
Priority to AT93914482T priority patent/ATE197951T1/de
Priority to DE69329727T priority patent/DE69329727T2/de
Priority to DK93914482T priority patent/DK0597088T3/da
Priority to CA002105867A priority patent/CA2105867C/fr
Priority to EP93914482A priority patent/EP0597088B1/fr
Application filed by Bioprojet SC, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Bioprojet SC
Publication of WO1993014070A2 publication Critical patent/WO1993014070A2/fr
Publication of WO1993014070A3 publication Critical patent/WO1993014070A3/fr
Anticipated expiration legal-status Critical
Priority to US08/663,679 priority patent/US5708171A/en
Priority to GR20010400244T priority patent/GR3035414T3/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des dérivés de l'imidazole répondant à la formule générale (IA) ou (IB). Procédés pour la préparation de ces composés et composition pharmaceutique les incorporant.
PCT/FR1993/000015 1992-01-10 1993-01-08 Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques Ceased WO1993014070A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002105867A CA2105867C (fr) 1992-01-10 1993-01-08 Derives imidazoles, leur preparation et leurs applications therapeutiques
US09/544,755 USRE37303E1 (en) 1992-01-10 1993-01-08 Imidazole compounds and their therapeutic applications
AT93914482T ATE197951T1 (de) 1992-01-10 1993-01-08 Neue imidazol derivate, ihre herstellung und therapeutische verwendung
DE69329727T DE69329727T2 (de) 1992-01-10 1993-01-08 Neue imidazol derivate, ihre herstellung und therapeutische verwendung
DK93914482T DK0597088T3 (da) 1992-01-10 1993-01-08 Nye imidazolderivater, deres fremstilling og terapeutiske anvendelser
US08/117,161 US5559113A (en) 1992-01-10 1993-01-08 Imidazole compounds and their therapeutic applications
JP51219193A JP3829259B2 (ja) 1992-01-10 1993-01-08 新規なイミダゾール誘導体、その製造及びその治療への応用
EP93914482A EP0597088B1 (fr) 1992-01-10 1993-01-08 Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques
US08/663,679 US5708171A (en) 1992-01-10 1996-06-14 Imidazole derivatives for pharmaceutical use
GR20010400244T GR3035414T3 (en) 1992-01-10 2001-02-14 Novel imidazole derivatives, their preparation and therapeutic applications.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9200189A FR2686084B1 (fr) 1992-01-10 1992-01-10 Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
FR92/00189 1992-01-10

Publications (2)

Publication Number Publication Date
WO1993014070A2 WO1993014070A2 (fr) 1993-07-22
WO1993014070A3 true WO1993014070A3 (fr) 1993-08-19

Family

ID=9425513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1993/000015 Ceased WO1993014070A2 (fr) 1992-01-10 1993-01-08 Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques

Country Status (12)

Country Link
US (2) US5559113A (fr)
EP (1) EP0597088B1 (fr)
JP (1) JP3829259B2 (fr)
AT (1) ATE197951T1 (fr)
CA (1) CA2105867C (fr)
DE (1) DE69329727T2 (fr)
DK (1) DK0597088T3 (fr)
ES (1) ES2154270T3 (fr)
FR (1) FR2686084B1 (fr)
GR (1) GR3035414T3 (fr)
PT (1) PT597088E (fr)
WO (1) WO1993014070A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9127304D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
GB9303825D0 (en) * 1993-02-25 1993-04-14 Smithkline Beecham Plc Novel compounds
GB9312893D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
JPH09505298A (ja) * 1993-11-15 1997-05-27 シェーリング コーポレイション Ｈ▲下３▼‐レセプターアンタゴニストとしてのフェニル‐アルキルイミダゾール
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
US6448282B1 (en) 1995-05-30 2002-09-10 Gliatech, Inc. 1H-4(5)-substituted imidazole derivatives
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
DE69619381T2 (de) * 1995-05-30 2002-11-21 Gliatech, Inc. 1h-4(5)substituierte imidazolderivate
WO1997029092A1 (fr) * 1996-02-09 1997-08-14 James Black Foundation Limited Ligands du recepteur de l'histamine h¿3?
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
GB2344588B (en) * 1997-07-25 2001-11-14 Black James Foundation 1H-4(5)-substituted imidazole derivatives their preparation and their use as histamine H 3 receptor ligands
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
GB9715814D0 (en) 1997-07-25 1997-10-01 Black James Foundation Histamine H3 receptor ligands
IL135729A0 (en) * 1997-11-07 2001-05-20 Schering Corp H3 receptor ligands of the phenyl-alkyl-imidazoles type
EP1028948B1 (fr) * 1997-11-07 2003-01-29 Schering Corporation Phenyl-alkyl-imidazoles utilises comme antagonistes du recepteur h 3?
US6034251A (en) * 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
DE19756212A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
US6136559A (en) 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
US6100279A (en) * 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
WO2000042023A1 (fr) 1999-01-18 2000-07-20 Novo Nordisk A/S Imidazoles substitues, leur preparation et utilisation
EP1031564A1 (fr) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibiteurs de la formation du nicotinamide mononucléotide et leur utilisation dans le traitement du cancer
US6211182B1 (en) * 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US20010047100A1 (en) * 2000-04-26 2001-11-29 Kjaersgaard Hans Joergen Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
WO2002013821A1 (fr) 2000-08-17 2002-02-21 Gliatech, Inc. Nouveaux imidazoles alicycliques utilises comme agents de h¿3?
AU2001292723A1 (en) * 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
CA2595994A1 (fr) * 2005-01-27 2006-08-03 Alma Mater Studiorum - Universita' Di Bologna Composes organiques convenant pour le traitement de la maladie d'alzheimer, utilisation et methode de fabrication
US20070299093A1 (en) * 2005-01-27 2007-12-27 Alma Mater Studiorum-Universitá Di Bologna Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation
EP1707203A1 (fr) 2005-04-01 2006-10-04 Bioprojet Utilization des allkylamines sans imidazoles comme ligandes du recepteur histamine H3 pour le traitement de la maladie de Parkinson, de l'apnee obstructive du sommeil, de la demence vasculaire et de la demence avec corps de Lewy
BRPI0610506A2 (pt) * 2005-04-20 2010-06-29 Johnson & Johnson moduladores de trombina de n-óxidos de piridina fluorados e processo para n-oxidação de heteroarilas contendo nitrogênio
EP1717235A3 (fr) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines et leur utilisation comme ligands du récepteur histaminique H3
EP1717233A1 (fr) * 2005-04-29 2006-11-02 Bioprojet Ligands du récepteur histaminique H3 et leur application thérapeutique
EP2968210B1 (fr) * 2013-03-12 2024-09-11 Bio-Pharm Solutions Co., Ltd. Composés phényl carmabate destinés à l'utilisation dans la prévention ou le traitement de l'épilepsie pédiatrique
CN109311882B (zh) * 2016-05-04 2022-02-11 Bci制药公司 作为蛋白激酶抑制剂的腺嘌呤衍生物

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE276541C (fr) *
DE332955C (de) * 1914-06-10 1921-02-15 Otto Gerngross Dr Verfahren zur Darstellung von 5(4)-Arylparaffinaminoparaffinimidazolen
US2301532A (en) * 1938-08-18 1942-11-10 Parke Davis & Co Biological product and process of obtaining same
US2376424A (en) * 1940-12-23 1945-05-22 Parke Davis & Co Biological product and process of obtaining same
FR1220002A (fr) * 1952-08-28 1960-05-20 Abbott Lab Procédé de préparation de 4 (5)-aryloxy-méthylimidazoles halosubstitués
FR2100822A1 (en) * 1970-06-25 1972-03-24 Smith Kline French Lab N-heterocyclyl)-alkyl-thioureas-selective antihistamines
GB1305547A (fr) * 1969-10-29 1973-02-07
GB1305548A (fr) * 1969-10-29 1973-02-07
GB1305549A (fr) * 1969-10-29 1973-02-07
GB1341375A (en) * 1969-11-19 1973-12-19 Smith Kline French Lab Aminoalkylimidazoles and process for their production
GB1531221A (en) * 1974-09-02 1978-11-08 Smith Kline French Lab Process for preparing guanidine derivatives
AU514574B2 (en) * 1977-04-21 1981-02-19 Smithkline Corporation Process for preparing 4-substituted imidazole compounds
EP0041359A1 (fr) * 1980-05-31 1981-12-09 Smith Kline & French Laboratories Limited Procédé de préparation de guanidines hétérocyclylalkyle; intermédiaires et leur préparation
EP0081324A2 (fr) * 1981-12-04 1983-06-15 Farmos Group Ltd. Dérivés substitués d'imidazole avec activité pharmacologique, leur préparation et utilisation
EP0199845A1 (fr) * 1985-04-02 1986-11-05 HEUMANN PHARMA GMBH & CO Dérivés d'imidazolylalkylguanidine, leur procédé de préparation et compositions les contenant
WO1987007891A1 (fr) * 1986-06-19 1987-12-30 Cedona Pharmaceuticals B.V. N-(ALKYLE A SUBSTITUTION 2)-N'-[(IMIDAZOLE-4-yl)ALKYLE]GUANIDINE
EP0262448A1 (fr) * 1986-09-15 1988-04-06 HEUMANN PHARMA GMBH & CO Dérivés d'imidazolylguanidine, leur procédé de préparation et les médicaments contenant ces composés
EP0291172A1 (fr) * 1987-04-14 1988-11-17 Glaxo Group Limited Dérivés de cétone
EP0302164A1 (fr) * 1987-08-07 1989-02-08 HEUMANN PHARMA GMBH & CO Esters d'acides guanidinecarboxyliques, procédés pour leur préparation et médicaments contenant ces composés
EP0315316A2 (fr) * 1987-10-02 1989-05-10 Beecham Group Plc Dérivés d'imidazole, procédé pour leur préparation, compositions pharmaceutiques les contenant, et leur application pharmaceutique
EP0338939A1 (fr) * 1988-04-22 1989-10-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dérivé de l'histamine, sa préparation et son application en thérapeutique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE701322C (de) * 1938-05-11 1941-01-14 Chemische Ind Ges Verfahren zur Darstellung von Imidazolin- und Tetrahydropyrimidinverbindungen
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US4072748A (en) * 1972-09-05 1978-02-07 Smith Kline & French Laboratories Limited Certain guanidine compounds, and their use as inhibitors of histamine activity
US4154834A (en) * 1975-12-29 1979-05-15 Smith Kline & French Laboratories Limited Substituted isocytosines having histamine H2 -antagonist activity
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them
DE3048266A1 (de) * 1980-12-20 1982-07-29 Bayer Ag, 5090 Leverkusen Substituierte 1-azolyl-butan-2one, verfahren zu ihrer herstellung und ihre verwendung als fungizide sowie als zwischenprodukte
JO1275B1 (en) * 1982-12-03 1985-04-20 هنري براون ثوماس Chemical process
US4489089A (en) * 1983-04-06 1984-12-18 American Cyanamid Company Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides
US4996221A (en) * 1987-01-13 1991-02-26 The Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives as immune modulators
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
NL8800998A (nl) * 1988-04-18 1989-11-16 Cedona Pharm Bv Werkwijze voor het bereiden van een al of niet gesubstitueerd 4(5)-(omega-aminoalkyl) imidazool.
CA2047041A1 (fr) * 1990-07-18 1992-01-19 John A. Lewis Procede de purification les capsides du virus de l'hepatite a
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE276541C (fr) *
DE332955C (de) * 1914-06-10 1921-02-15 Otto Gerngross Dr Verfahren zur Darstellung von 5(4)-Arylparaffinaminoparaffinimidazolen
US2301532A (en) * 1938-08-18 1942-11-10 Parke Davis & Co Biological product and process of obtaining same
US2376424A (en) * 1940-12-23 1945-05-22 Parke Davis & Co Biological product and process of obtaining same
FR1220002A (fr) * 1952-08-28 1960-05-20 Abbott Lab Procédé de préparation de 4 (5)-aryloxy-méthylimidazoles halosubstitués
GB1305547A (fr) * 1969-10-29 1973-02-07
GB1305548A (fr) * 1969-10-29 1973-02-07
GB1305549A (fr) * 1969-10-29 1973-02-07
GB1341375A (en) * 1969-11-19 1973-12-19 Smith Kline French Lab Aminoalkylimidazoles and process for their production
FR2100822A1 (en) * 1970-06-25 1972-03-24 Smith Kline French Lab N-heterocyclyl)-alkyl-thioureas-selective antihistamines
GB1531221A (en) * 1974-09-02 1978-11-08 Smith Kline French Lab Process for preparing guanidine derivatives
AU514574B2 (en) * 1977-04-21 1981-02-19 Smithkline Corporation Process for preparing 4-substituted imidazole compounds
EP0041359A1 (fr) * 1980-05-31 1981-12-09 Smith Kline & French Laboratories Limited Procédé de préparation de guanidines hétérocyclylalkyle; intermédiaires et leur préparation
EP0081324A2 (fr) * 1981-12-04 1983-06-15 Farmos Group Ltd. Dérivés substitués d'imidazole avec activité pharmacologique, leur préparation et utilisation
EP0199845A1 (fr) * 1985-04-02 1986-11-05 HEUMANN PHARMA GMBH & CO Dérivés d'imidazolylalkylguanidine, leur procédé de préparation et compositions les contenant
WO1987007891A1 (fr) * 1986-06-19 1987-12-30 Cedona Pharmaceuticals B.V. N-(ALKYLE A SUBSTITUTION 2)-N'-[(IMIDAZOLE-4-yl)ALKYLE]GUANIDINE
EP0262448A1 (fr) * 1986-09-15 1988-04-06 HEUMANN PHARMA GMBH & CO Dérivés d'imidazolylguanidine, leur procédé de préparation et les médicaments contenant ces composés
EP0291172A1 (fr) * 1987-04-14 1988-11-17 Glaxo Group Limited Dérivés de cétone
EP0302164A1 (fr) * 1987-08-07 1989-02-08 HEUMANN PHARMA GMBH & CO Esters d'acides guanidinecarboxyliques, procédés pour leur préparation et médicaments contenant ces composés
EP0315316A2 (fr) * 1987-10-02 1989-05-10 Beecham Group Plc Dérivés d'imidazole, procédé pour leur préparation, compositions pharmaceutiques les contenant, et leur application pharmaceutique
EP0338939A1 (fr) * 1988-04-22 1989-10-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dérivé de l'histamine, sa préparation et son application en thérapeutique

Also Published As

Publication number Publication date
JP3829259B2 (ja) 2006-10-04
JPH06506003A (ja) 1994-07-07
FR2686084A1 (fr) 1993-07-16
DE69329727T2 (de) 2001-04-12
ATE197951T1 (de) 2000-12-15
GR3035414T3 (en) 2001-05-31
CA2105867C (fr) 2005-07-12
WO1993014070A2 (fr) 1993-07-22
CA2105867A1 (fr) 1993-07-11
ES2154270T3 (es) 2001-04-01
US5708171A (en) 1998-01-13
DK0597088T3 (da) 2001-04-09
PT597088E (pt) 2001-04-30
EP0597088A1 (fr) 1994-05-18
DE69329727D1 (de) 2001-01-11
EP0597088B1 (fr) 2000-12-06
FR2686084B1 (fr) 1995-12-22
US5559113A (en) 1996-09-24

Similar Documents

Publication Publication Date Title
WO1993014070A3 (fr) Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques
AU687909B2 (en) Protein kinase C inhibitors
IL105729A0 (en) Azepine derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
AU3504393A (en) N-sulphonyl-2-oxoindole derivatives having affinity for vasopressin and/or ocytocin receptors
CA2111527A1 (fr) Phosphonooxymethylethers de derives du taxane
AU7026794A (en) Phosphonooxymethyl ethers of taxane derivatives
IL140093A0 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
AU1924699A (en) Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
CA2233178A1 (fr) (methylsulfonyl)phenyl-2-(5h)-furanones en tant qu'inhibiteurs du cox-2
CA2091360A1 (fr) Fuorate de mometasone monohydrate, son procede de fabrication et ses compositions pharmaceutiques
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
CA2163706A1 (fr) Derives amino-acides de paclitaxel
CA2338600A1 (fr) Nouveaux composes de thiazolopyrimidine
UA70921C2 (uk) Похідні 2-(імінометил)амінофенілу, спосіб їх одержання (варіанти) та фармацевтична композиція, що містить ці сполуки
CA2152771A1 (fr) Derives 7-o-ether de taxane
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
ZA93821B (en) New derivatives of baccatin III and of 10-deacetyibaccatin III, their preparation and the pharmaceutical compositions which contain them.
CA2219359A1 (fr) Derives hydantoine utilises comme produits intermediaires pour principes actifs pharmaceutiques
AU7498494A (en) New bis-naphthalimides for the treatment of cancer
AU5491194A (en) Cytotoxic and antiviral compound
IL104471A0 (en) Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
AU3580995A (en) Derivatives of carbohydrates and compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1993914482

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2105867

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1993914482

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993914482

Country of ref document: EP